Literature DB >> 20195642

A unique neurological presentation of Wegener's granulomatosis.

David Selewski, Suresh K Mukherji, David Kershaw.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20195642     DOI: 10.1007/s00467-010-1482-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  6 in total

1.  Standardized neurologic evaluations of 128 patients with Wegener granulomatosis.

Authors:  K de Groot; D K Schmidt; A C Arlt; W L Gross; E Reinhold-Keller
Journal:  Arch Neurol       Date:  2001-08

Review 2.  Meningeal involvement in Wegener's granulomatosis is associated with localized disease.

Authors:  G Di Comite; E P Bozzolo; L Praderio; M Tresoldi; M G Sabbadini
Journal:  Clin Exp Rheumatol       Date:  2006 Mar-Apr       Impact factor: 4.473

3.  Wegener granulomatosis in children and adolescents: clinical presentation and outcome.

Authors:  M Rottem; A S Fauci; C W Hallahan; G S Kerr; R Lebovics; R Y Leavitt; G S Hoffman
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

4.  Clinical features and outcome of pediatric Wegener's granulomatosis.

Authors:  J D Akikusa; R Schneider; E A Harvey; D Hebert; P S Thorner; R M Laxer; E D Silverman
Journal:  Arthritis Rheum       Date:  2007-06-15

5.  Central nervous system involvement in Wegener granulomatosis.

Authors:  Raphaèle Seror; Alfred Mahr; Jacky Ramanoelina; Christian Pagnoux; Pascal Cohen; Loïc Guillevin
Journal:  Medicine (Baltimore)       Date:  2006-01       Impact factor: 1.889

6.  Clinical features in 17 paediatric patients with Wegener granulomatosis.

Authors:  Vladimir M Belostotsky; Vanita Shah; Michael J Dillon
Journal:  Pediatr Nephrol       Date:  2002-08-08       Impact factor: 3.714

  6 in total
  1 in total

Review 1.  Cranial neuropathies in granulomatosis with polyangiitis (Wegener's): a case-based review.

Authors:  Ana Söderström; Sylvie Revaz; Jean Dudler
Journal:  Clin Rheumatol       Date:  2013-12-19       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.